DermatologyResearch Phase

Palmitoyl Tripeptide-1

Topical

Overview

Palmitoyl Tripeptide-1 is a synthetic lipopeptide comprising a tripeptide linked to palmitic acid, designed to mimic a portion of the Type I collagen molecule. By binding to fibroblast receptors, it is hypothesized to trigger signaling cascades that upregulate collagen and glycosaminoglycan synthesis.

Mechanism of Action

This peptide is widely incorporated into topical anti-aging formulations to promote dermal matrix regeneration and reduce the appearance of fine lines..

Research Summary & Key Findings

In vitro studies have demonstrated increased collagen I and fibronectin production in cultured human dermal fibroblasts. Clinical studies, including small split-face trials, have reported improvements in wrinkle depth and skin elasticity, though many are sponsored by ingredient manufacturers and published outside high-impact dermatology journals.

Clinical Status

Research Phase

Palmitoyl Tripeptide-1 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers Palmitoyl Tripeptide-1 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Palmitoyl Tripeptide-1.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.